|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 44, 754-761, April 2003
Copyright © 2003 by Lipid Research, Inc.
Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients
* Institute for Clinical Chemistry, University of Regensburg, Germany
Laboratory Medicine, Department of Anesthesiology, University of Regensburg, Germany
Department of Internal Medicine I, University of Regensburg, Germany
** Department of Surgery, University of Regensburg, Germany
1 To whom correspondence should be addressed. e-mail: gerd.schmitz{at}klinik.uni-regensburg.de
Recent data indicate that ceramide (Cer) and lysophosphatidylcholine (LPC) regulate immune cell functions. Since these bioactive lipids are generated in blood plasma by inflammatory lipases, we hypothesized that they may be involved in the process of acute systemic sepsis. In order to provide support for this hypothesis, we analyzed the plasma levels of Cer and LPC by quantitative tandem mass spectrometry in 102 sepsis patients starting with the day at which the sepsis criteria were fulfilled for the first time, as well as on day 4 and day 11. The values were compared with 56 healthy controls and correlated with sepsis-related mortality within 30 days of study entry. Most Cer species were increased in sepsis patients, while all LPC species were markedly decreased. In addition, we determined the molar ratios with their precursor molecules sphingomyelin (SPM) and phosphatidylcholine (PC), which reflect the enzymatic reactions responsible for their formation. Species-specific as well as total Cer-SPM ratios were increased, whereas LPC-PC ratios were decreased in sepsis patients. The increased Cer-SPM ratios as well as the decreased LPC-PC ratios showed a strong predictive power for sepsis-related mortality.
Together with existing data from in vitro experiments and animal models, the results provide the first ex vivo indication for the role of Cer and lysophospholipids in systemic inflammation in humans.
Abbreviations: AUC, area under the curve; Cer, ceramide; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; ROC, receiver operating curve; SPM, sphingomyelin
Supplementary key words outcome • lipoproteins • sphingomyelinase • phospholipase • SAPS score • prognostic marker
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B.-C. Chen, H.-M. Chang, M.-J. Hsu, C.-M. Shih, Y.-H. Chiu, W.-T. Chiu, and C.-H. Lin Peptidoglycan Induces Cyclooxygenase-2 Expression in Macrophages by Activating the Neutral Sphingomyelinase-Ceramide Pathway J. Biol. Chem., July 31, 2009; 284(31): 20562 - 20573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wiesner, K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry J. Lipid Res., March 1, 2009; 50(3): 574 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, X. Chen, R. G. Salomon, and T. M. McIntyre Platelet Activation by Low Concentrations of Intact Oxidized LDL Particles Involves the PAF Receptor Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Haus, S. R. Kashyap, T. Kasumov, R. Zhang, K. R. Kelly, R. A. DeFronzo, and J. P. Kirwan Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance Diabetes, February 1, 2009; 58(2): 337 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhao, A. Peter, J. Fritsche, M. Elcnerova, A. Fritsche, H.-U. Haring, E. D. Schleicher, G. Xu, and R. Lehmann Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab, February 1, 2009; 296(2): E384 - E393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Uhlig and E. Gulbins Sphingolipids in the Lungs Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1100 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cuzzocrea, R. Di Paola, T. Genovese, E. Mazzon, E. Esposito, C. Crisafulli, P. Bramanti, and D. Salvemini Anti-Inflammatory and Anti-Apoptotic Effects of Fumonisin B1, an Inhibitor of Ceramide Synthase, in a Rodent Model of Splanchnic Ischemia and Reperfusion Injury J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 45 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meron-Sudai, A. Matityahou, Y. Keisari, K. H. Cox, D. L. Hasty, and I. Ofek Lipoteichoic Acid Synergizes with Glycosphingolipids To Potently Stimulate Secretion of Interleukin-6 from Human Blood Cells Clin. Vaccine Immunol., September 1, 2008; 15(9): 1309 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Masukawa, H. Narita, E. Shimizu, N. Kondo, Y. Sugai, T. Oba, R. Homma, J. Ishikawa, Y. Takagi, T. Kitahara, et al. Characterization of overall ceramide species in human stratum corneum J. Lipid Res., July 1, 2008; 49(7): 1466 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. von Bismarck, C.-F. Garcia Wistadt, K. Klemm, S. Winoto-Morbach, U. Uhlig, S. Schutze, D. Adam, B. Lachmann, S. Uhlig, and M. F. Krause Improved Pulmonary Function by Acid Sphingomyelinase Inhibition in a Newborn Piglet Lavage Model Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1233 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E.M. Groener, B. J.H.M. Poorthuis, S. Kuiper, M. T.J. Helmond, C. E.M. Hollak, and J. M.F.G. Aerts HPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma Clin. Chem., April 1, 2007; 53(4): 742 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Masukawa, H. Tsujimura, and H. Narita Liquid chromatography-mass spectrometry for comprehensive profiling of ceramide molecules in human hair J. Lipid Res., July 1, 2006; 47(7): 1559 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sparkman, H. Chandru, and V. Boggaram Ceramide decreases surfactant protein B gene expression via downregulation of TTF-1 DNA binding activity Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L351 - L358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gulbins and P. L. Li Physiological and pathophysiological aspects of ceramide Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R11 - R26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mehta Lysophosphatidylcholine: an enigmatic lysolipid Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L174 - L175. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Gon, M. R. Wood, W. B. Kiosses, E. Jo, M. G. Sanna, J. Chun, and H. Rosen S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF PNAS, June 28, 2005; 102(26): 9270 - 9275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lin, E. J. Welch, X.-P. Gao, A. B. Malik, and R. D. Ye Lysophosphatidylcholine Modulates Neutrophil Oxidant Production through Elevation of Cyclic AMP J. Immunol., March 1, 2005; 174(5): 2981 - 2989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |